Publications by authors named "Mami Shintani-Tachi"
Aims: Insulin therapy is a cornerstone in type 2 diabetes mellitus (T2DM) management, but its use is associated with several barriers, including hypoglycaemia, fear of injections and high costs. We compared the risk of insulin initiation and other treatment intensification between patients with T2DM newly treated with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus those newly treated with a dipeptidyl peptidase-4 inhibitor (DPP4i).
Materials And Methods: This Japanese retrospective cohort study was conducted between 1 January 2015 and 31 March 2023 using the JMDC Claims Database.
Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World Data.
Masaya Koshizaka Tomoaki Tatsumi Fumiko Kiyonaga Yoshinori Kosakai Yoko Yoshinaga Mami Shintani-Tachi
Diabetes Ther
November 2024
Article Synopsis
- Diabetic retinopathy (DR) is a common eye complication in type 2 diabetes, significantly affecting patients' vision and quality of life.
- This study analyzed data from patients in Japan to compare the risk of DR in those treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP-4i).
- Results showed that patients on SGLT2i had a lower incidence of DR diagnoses compared to those on DPP-4i, indicating SGLT2i may help prevent DR in early-stage type 2 diabetes.